We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EMN:NYSEEastman Chemical Company Analysis

Data as of 2026-07-17 - not real-time

$69.16

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

PE ratio sits near twenty while the forward multiple is roughly half that, creating a noticeable pricing gap. The dividend yield is close to five percent, but a payout ratio approaching ninety percent raises sustainability concerns. Technical gauges show a neutral trend, with the 20‑day moving average just above the 200‑day average and the RSI lingering in the mid‑40s. The MACD histogram has turned positive, suggesting a modest bullish bias, yet overall momentum remains subdued. Volatility over the past month exceeds thirty percent, and a beta slightly above one points to heightened sensitivity to market swings. Price action is bounded by a support zone around sixty‑six dollars and resistance near seventy‑five dollars, offering a clear trading range. Analysts collectively rate the stock as a buy, with a mean target price in the low eighties, implying an upside of roughly nineteen percent.
DCF valuation assigns a fair value under eight dollars, a stark contrast that flags potential overvaluation. Revenue contraction and a high debt‑to‑equity ratio add leverage risk. Operating cash flow remains solid, but free cash flow is modest, limiting flexibility for debt reduction or dividend growth. The basic materials sector is cyclical, exposing EMN to commodity price swings and regulatory scrutiny in chemicals. Geographic exposure spans the United States and China, introducing geopolitical and currency considerations. Given the blend of a generous dividend, modest growth prospects, and a sizable valuation premium, the stock sits at the intersection of value and income but leans toward caution. Investors should weigh the dividend appeal against sustainability concerns and the valuation gap before committing capital.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near support zone
  • neutral technical indicators
  • decreasing volume trend

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • attractive dividend yield
  • valuation gap relative to analyst targets
  • stable operating cash flow

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • high debt‑to‑equity ratio
  • negative revenue growth
  • DCF fair value far below market price

Key Metrics & Analysis

Financial Health

Revenue Growth-4.90%
Profit Margin4.62%
P/E Ratio20.0
ROE6.63%
ROA3.53%
Debt/Equity89.62
P/B Ratio1.3
Op. Cash Flow$1.0B
Free Cash Flow$434.0M

Technical Analysis

TrendNeutral
RSI48.0
Support$66.00
Resistance$75.06
MA 20$68.96
MA 50$71.81
MA 200$68.74
MACDBullish
VolumeDecreasing
Fear & Greed Index91.55

Valuation

Fair Value$7.66
Target Price$82.33
Upside/Downside19.05%
GradeOvervalued
TypeValue
Dividend Yield4.95%

Risk Assessment

Beta1.11
Volatility32.27%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.